High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis
- 1 June 2007
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (10) , 1253-1261
- https://doi.org/10.1097/qad.0b013e3281a3bec2
Abstract
To determine the natural history of HIV infection following peripartum single-dose nevirapine (sd-NVP) prophylaxis in a resource-limited country, and to assess implications for antiretroviral therapy (ART) roll-out programmes. Infants of HIV-infected mothers in KwaZulu-Natal, South Africa, were tested on days 1 and 28 to detect intrauterine (IU) and intrapartum (IP) infection. Infant follow-up included monthly viral load and CD4 cell measurement. ART was initiated at infant CD4 cell% < or = 20%. In 740 infants born to 719 HIV-infected women, mother-to-child transmission (MTCT) was 10.3% (69% IU, 31% IP). Median viral load was higher in mothers of infants infected IP than IU (279 000 versus 86 600 copies/ml; P = 0.039) and lower in mothers of uninfected infants (median 26 750 copies/ml; P < 0.001). Peak viraemia was higher in infants infected IP than IU (5 160 000 versus 984 000 copies/ml; P < 0.001). Median viral load at birth in IU-infected infants (155 000 copies/ml) fell 1.4 log to 6510 copies/ml by day 5 and was beneath the detection limit using dried blood spot analysis in 38% of infants. CD4 cell% declined rapidly, to < or = 20% in 70% and < or = 25% in 85% [current World Health Organization (WHO) criteria for initiating ART] of infants by 6 months. MTCT was reduced by sd-NVP through an effect on IP transmission. Where MTCT occurred despite NVP, two-thirds of transmissions arose IU; IP-infected babies were born to mothers with very high viral load. Disease progression was particularly rapid, 85% infants meeting WHO criteria for ART within 6 months. These findings argue for more effective MTCT-prevention programmes in resource-limited countries.Keywords
This publication has 24 references indexed in Scilit:
- Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysisThe Lancet, 2004
- Morbidity and Mortality in Breastfed and Formula-Fed Infants of HIV-1–Infected WomenJAMA, 2001
- 18-Month mortality and perinatal exposure to zidovudine in West AfricaAIDS, 2001
- Natural History of Human Immunodefiency Virus Type 1 Infection in Children: A Five-Year Prospective Study in RwandaPublished by American Academy of Pediatrics (AAP) ,1999
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999
- Mortality after the first year of life among human immunodeficiency virus type 1-infected and uninfected childrenThe Pediatric Infectious Disease Journal, 1999
- Distinct Risk Factors for Intrauterine and Intrapartum Human Immunodeficiency Virus Transmission and Consequences for Disease Progression in Infected ChildrenThe Journal of Infectious Diseases, 1999
- Early Prognostic Indicators in Primary Perinatal Human Immunodeficiency Virus Type 1 Infection: Importance of Viral RNA and the Timing of Transmission on Long-Term OutcomeThe Journal of Infectious Diseases, 1998
- Neonatal Characteristics in Rapidly Progressive Perinatally Acquired HIV-1 DiseaseJAMA, 1996
- Longitudinal Study of 94 Symptomatic Infants With Perinatally Acquired Human Immunodeficiency Virus InfectionAmerican Journal of Diseases of Children, 1990